Ivermectin for preventing and treating COVID-19
Maria Popp, Miriam Stegemann, Maria-Inti Metzendorf, Susan Gould, Peter Kranke, Patrick Meybohm, Nicole Skoetz, Stephanie Weibel
Cochrane Database of Systematic Reviews, doi:10.1002/14651858.cd015017.pub2
Analysis 1.2. Comparison 1: Ivermectin compared to placebo or standard of care for people with moderate-to-severe COVID-19 treated in the inpatient setting, Outcome 2: Worsening of clinical status -need for invasive mechanical ventilation up to 28 days (primary analysis
CONSORT 2010 Statement Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Medicine 2010;8:18.
COVID Guidelines India 2021 Covid Management Guidelines India Group. COVID Management Guidelines India. indiacovidguidelines.org/ivermectin/ (accessed 15 May 2021).
COVID-NMA Working Group COVID-NMA working group. The COVID-NMA initiative: a living mapping and living systematic review of Covid-19 trials. covidnma.com (accessed prior to 1 July 2021).
Cochrane
Library Trusted evidence. Informed decisions. Better health.
Supplementary File_Ivermectin_Risk of Bias Weibel S, Popp M. Supplementary File_Ivermectin_Risk of Bias Excel Tool (Version 1). Zenodo 2021. • Inclusion criteria: aged 18-65 years; admitted to hospital within last 7 days; presence of fever (37.5 °C), cough, sore throat, or a combination; diagnosed positive for SARS-CoV-2 by rRT-PCR • Exclusion criteria: allergic to ivermectin or doxycycline, or if here was the potential for a drug-drug interaction with ivermectin or doxycycline; had chronic illnesses (e.g. ischaemic heart disease, heart failure, documented cardiomyopathy, chronic kidney disease, chronic liver disease); had received ivermectin or doxycycline (or both) in the last 7 days; were pregnant or lactating; or had participated in any other clinical trial within last month Interventions
Cochrane Database of Systematic Reviews
Study characteristics
..
References
Deeks, Higgins, Altman, Chapter 10: Analysing data and undertaking meta-analyses
Garegnani, Madrid, Meza, Misleading clinical evidence and systematic reviews on ivermectin for COVID-19, BMJ Evidence Based Medicine
German Awmf Guideline, None
Goetz, Magar, Dornfeld, Giese, Pohlmann et al., Influenza A viruses escape from MxA restriction at the expense of e icient nuclear vRNP import, Scientific Reports,
doi:10.1038/srep23138
González-Canga, None
González-Canga, Sahagún-Prieto, Diez-Liébana, Fernández-Martínez, Vega et al., The pharmacokinetics and interactions of ivermectin in humans, Journal of the American Association of Pharmaceutical Scientists,
doi:10.1208/s12248-007-9000-9]Herrmann2020
Herrmann, Adam, Notz, Helmer, Sonntagbauer et al., COVID-19 induced acute respiratory distress syndrome -a multicenter observational study
Higgins, Lasserson, Chandler, Tovey, Thomas et al., Methodological Expectations of Cochrane Intervention Reviews
Hill, Abdulamir, Ahmed, Ashgar, Babalola et al., Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection,
doi:10.21203/rs.3.rs-148845/v1
Ivmmeta, com Ivermectin for COVID-19: real-time meta analysis of 60 studies
Karagiannidis, Mostert, Hentschker, Voshaar, Malzahn et al., Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study, Lancet Respiratory Medicine,
doi:10.1016/S2213-2600(20)30316-7
Kluge, Janssens, Welte, Weber-Carstens, Schälte et al., S3-Guideline -recommendations on Inpatient Treatment of Patients With COVID-19
Kobayashi, Jung, Linton, Kinoshita, Hayashi et al., Communicating the risk of death from novel coronavirus disease (COVID-19), Journal of Clinical Medicine,
doi:10.3390/jcm9020580
Panahi, Poursaleh, Goldust, The e icacy of topical and oral ivermectin in the treatment of human scabies, Annals of Parasitology
Prescott, Girard, RECOVERY 2021 Recovery Collaborative Group. Dexamethasone in hospitalized patients with Covid-19, New England Journal of Medicine,
doi:10.1001/jama.2020.14103
Rodríguez-Mega, None
Schünemann, Higgins, Vist, Glasziou, Akl et al., Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence
Siemieniuk, Rochwerg, Agoritsas, Lamontagne, Leo et al., A living WHO guideline on drugs for Covid-19, BMJ,
doi:10.1136/bmj.m3379
Singh, Ryan, Kredo, Chaplin, Fletcher, Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19, Cochrane Database of Systematic Reviews,
doi:10.1002/14651858.CD013587.pub2
Sterne, Savović, Page, Elbers, Blencowe et al., RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ,
doi:10.1136/bmj.l4898